AI-generated summary
The authors report a pilot randomized, double-blind, placebo-controlled trial of 33 participants with mild cognitive impairment or mild Alzheimer's disease, combining tDCS with intranasal 850 nm near-infrared stimulation over 50 sessions. The active group showed improvements on MMSE and ADAS-Cog scores compared with baseline, with no serious adverse events reported. The authors describe this as a pilot study with a small sample.
- Participants
- 33
- Who or what was studied
- Patients with mild cognitive impairment or mild Alzheimer's disease
- Wavelengths
- 850 nm
- Limits stated in the abstract
- The abstract describes this as a small pilot study, and the comparison is reported as within-group changes in the active arm without detailed between-group results.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Mild cognitive impairment, Placebo-controlled, Near-infrared, Transcranial direct current stimulation, Photobiomodulation, Trial registration, Cognitive decline, Neuromodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.